Tessera Therapeutics: Funding, Investors & Team (Sep 2026)
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Tessera Therapeutics has raised $300M across 2 funding rounds on record, the most recent an undisclosed round announced in Mar 2026.
Tessera Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Tessera Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Tessera Therapeutics raised $300M in a Series C announced in Apr 2022.
3.9 years later, an undisclosed round was announced in Mar 2026 with no disclosed amount.
Tessera Therapeutics Founders and Leadership Team
Contact details for the Tessera Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Tessera Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like Tessera Therapeutics in Biotechnology and Cambridge
Companies Similar to Tessera Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Tessera Therapeutics Funding FAQs
What does Tessera Therapeutics do?
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
How much funding has Tessera Therapeutics raised?
Tessera Therapeutics has raised $300M across 2 rounds on record.
When did Tessera Therapeutics last raise funding?
Tessera Therapeutics' most recent funding round on record was announced in Mar 2026. The amount was not disclosed.
Who founded Tessera Therapeutics?
FundedIQ lists Michael Severino (Founder), Robert Citorik (Founder) at Tessera Therapeutics.
Where is Tessera Therapeutics headquartered?
Tessera Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Tessera Therapeutics have?
Tessera Therapeutics is in the 101-250 employee band.
About FundedIQ's Tessera Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tessera Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.